CompanyGraph
At a glance
- Depends onUpstream position: supplies 5 industries, depends on 1
- ScaleMarket cap is $2.11B, above the global median of $1.15B
- PositionGross margin is 82.1%, higher than 95% of its Medical Instruments & Supplies peers (median 54%)
- Interpretations11 currently firing — 11
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
4.99%Above 5Y avg (1.74%)
Annual Rate
CNY 2.00Paid semi-annual
Payout Ratio
45.9%Sustainable
Payback Period
26.8 yr
Last Ex-Dividend
May 22, 2026
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
14.23BCNY2.11B · vs all stocks (USD)
Trailing P/E
19.09xvs Medical Instruments & Supplies peers
Revenue (TTM)
2.62BCNY389.13M · vs all stocks (USD)
Profit Margin
28.87%vs Medical Instruments & Supplies peers
Beta
0.1000xvs all stocks
52-Week Change
-13.83%vs all stocks
Forward Annual Dividend Yield
4.99%vs all stocks
Market Capitalization
14.23BCNY2.11B · vs all stocks (USD)
Enterprise Value
14.25BCNY2.12B · vs all stocks (USD)
Trailing P/E
19.09xvs Medical Instruments & Supplies peers
Forward P/E
9.35xvs Medical Instruments & Supplies peers
PEG Ratio
-8.35xvs Medical Instruments & Supplies peers
Price to Sales (TTM)
5.48xvs Medical Instruments & Supplies peers
Price to Book (MRQ)
6.62xvs Medical Instruments & Supplies peers
Enterprise to Revenue
5.44xvs Medical Instruments & Supplies peers
Enterprise to EBITDA
14.88xvs Medical Instruments & Supplies peers
Gross Margin
82.05%vs Medical Instruments & Supplies peers
Profit Margin
28.87%vs Medical Instruments & Supplies peers
Operating Margin
33.57%vs Medical Instruments & Supplies peers
Return on Assets (TTM)
21.17%vs Medical Instruments & Supplies peers
Return on Equity (TTM)
38.51%vs Medical Instruments & Supplies peers
Revenue (TTM)
2.62BCNY389.13M · vs all stocks (USD)
Revenue per Share (TTM)
7.36CNYUpdated Aug 19, 2026Quarterly Revenue Growth
27.50%vs Medical Instruments & Supplies peers
Gross Profit (TTM)
2.13BCNY315.73M · vs all stocks (USD)
EBITDA (TTM)
934.70MCNY138.82M · vs all stocks (USD)
Net Income (TTM)
756.37MCNY112.34M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
41.50%vs Medical Instruments & Supplies peers
Operating Cash Flow (TTM)
771.21MCNY114.54M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
426.52MCNY63.35M · vs all stocks (USD)
Forward Annual Dividend Rate
2.00CNYUpdated Aug 19, 2026Forward Annual Dividend Yield
4.99%vs all stocks
Trailing Annual Dividend Rate
1.48CNYUpdated Aug 19, 2026Trailing Annual Dividend Yield
3.70%vs all stocks
5-Year Average Dividend Yield
1.74%vs all stocks
Payout Ratio
45.91%vs Medical Instruments & Supplies peers
Revenue
2.47BCNYFY2025 · Dec 31, 2025Cost of Goods Sold
465.96MCNYFY2025 · Dec 31, 2025Gross Profit
2.01BCNYFY2025 · Dec 31, 2025Operating Income
843.77MCNY125.32M · vs all stocks (USD)
Pre-tax Income
800.28MCNYFY2025 · Dec 31, 2025Income Tax Expense
104.42MCNYFY2025 · Dec 31, 2025Net Income
695.86MCNYFY2025 · Dec 31, 2025EBIT
804.71MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
934.70MCNYFY2025 · Dec 31, 2025Research & Development
225.91MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
459.35MCNYFY2025 · Dec 31, 2025Other Operating Expenses
32.83MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
2.25MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
4.44MCNYFY2025 · Dec 31, 2025EPS (Basic)
1.95CNYFY2025 · Dec 31, 2025EPS (Diluted)
1.95CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
356.53MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
356.53MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
695.86MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
486.47MCNYFY2025 · Dec 31, 2025Free Cash Flow
215.99MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
386.43MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
695.86MCNYFY2025 · Dec 31, 2025Other Non-cash Items
8.70MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-174.85MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-43.23MCNYFY2025 · Dec 31, 2025Capital Expenditures
-270.48MCNYFY2025 · Dec 31, 2025Other Investing Activity
740.80KCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-269.74MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
181.00MCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-311.00MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-351.08MCNYFY2025 · Dec 31, 2025Other Financing Charges
22.69MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-458.39MCNYFY2025 · Dec 31, 2025Shares Outstanding
357.32MSharesUpdated Aug 19, 2026Float Shares
245.56MSharesUpdated Aug 19, 2026% Held by Insiders
32.52%vs all stocks
% Held by Institutions
3.95%vs all stocks
Total Cash (MRQ)
574.03MCNY85.26M · vs all stocks (USD)
Total Cash per Share (MRQ)
1.61CNYUpdated Aug 19, 2026Total Debt (MRQ)
80.94MCNY12.02M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.0370xvs Medical Instruments & Supplies peers
Current Ratio (MRQ)
2.23xvs Medical Instruments & Supplies peers
Book Value per Share (MRQ)
6.12CNYUpdated Aug 19, 2026Total Assets
2.54BCNY377.09M · vs all stocks (USD)
Total Current Assets
930.73MCNYFY2025 · Dec 31, 2025Total Liabilities
560.93MCNYFY2025 · Dec 31, 2025Total Non-current Assets
1.61BCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
60.10MCNYFY2025 · Dec 31, 2025Total Current Liabilities
500.83MCNYFY2025 · Dec 31, 2025Cash
385.87MCNYFY2025 · Dec 31, 2025Cash Equivalents
7.84MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
393.71MCNYFY2025 · Dec 31, 2025Accounts Receivable
262.99MCNYFY2025 · Dec 31, 2025Inventory
189.23MCNYFY2025 · Dec 31, 2025Accounts Payable
35.49MCNYFY2025 · Dec 31, 2025Short-term Debt
77.65MCNYFY2025 · Dec 31, 2025Other Current Liabilities
19.72MCNYFY2025 · Dec 31, 2025Long-term Debt
4.38MCNYFY2025 · Dec 31, 2025Common Stock (Book)
246.43MCNYFY2025 · Dec 31, 2025Retained Earnings
777.05MCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
1.98BCNY293.78M · vs all stocks (USD)
52-Week Low
35.10CNYUpdated Aug 19, 202652-Week High
59.07CNYUpdated Aug 19, 202652-Week Change
-13.83%vs all stocks
Beta
0.1000xvs all stocks
50-Day MA
40.39CNYUpdated Aug 19, 2026200-Day MA
45.89CNYUpdated Aug 19, 2026Avg 10-Day Volume
8.92MSharesUpdated Aug 19, 2026Avg 30-Day Volume
8.78MSharesUpdated Aug 19, 2026Diluted EPS (TTM)
2.12CNYUpdated Aug 19, 202611 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
MRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total Liabilities
Cash covers most of its debt, with earnings high against its liabilities.
Reads
How does this company use capital?
Three Asset-Base Ratios Elevated
It gets more sales from its assets than its industry does, and a lot of profit from them too.
Reads
Cash Backing With Revenue And Income Streaks
Revenue has risen in each of three years, profit in all three, and it holds more cash than debt.
Reads
Industry-Benchmarked ROA and Margin Elevated
Returns and margins have sat in the top of its industry across five years.
Reads
Industry-Benchmarked Return on Capital Elevated
It earns more on its assets and its equity than its industry, and gets more sales from those assets.
Reads
Operating Income Growing With Multi-Year Revenue Growth
Revenue up in each of five years, with operating income up in each of four.
Reads
Three Margin Ratios Elevated Across Gross, Operating, And Net Levels
Its gross and net margins are high for its industry, and its operating margin is high outright.
Reads
ROE, ROA, And Operating ROA Elevated
It earns more on its equity than its industry does, and on its assets too — not on borrowing alone.
Reads
Is this company growing?
Multi-Year Revenue And Profit Growth
Revenue and earnings have both grown steadily across six years.
Reads
Multi-Year Revenue, Profit, And Income Growth
Revenue has risen in each of three years, gross profit in each of four, and it has made a profit in all five.
Reads
Where is this company structurally exposed?
Ulcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
It sits well below its peak, and the fall has been both deep and long.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Gross margin is 82.1%, higher than 95% of its Medical Instruments & Supplies peers (median 54%)Significant
Gross margin: 0.82Industry median: 0.54Industry P95: 0.78Peers compared: 35.00
Return on equity is 38.5%, higher than 95% of its Medical Instruments & Supplies peers (median 5.6%)Significant
Return on equity: 0.39Industry median: 0.06Industry P95: 0.17Peers compared: 35.00
Return on assets is 21.2%, higher than 95% of its Medical Instruments & Supplies peers (median 3.2%)Significant
Return on assets: 0.21Industry median: 0.03Industry P95: 0.15Peers compared: 35.00
Financial Health
High earnings qualityNotable
Earnings Quality Score: 0.54
Supply Chain
Upstream position: supplies 5 industries, depends on 1Notable
Outgoing: 5.00Incoming: 1.00
Scale
Market cap is $2.11B, above the global median of $1.15BNotable
Market cap (USD): 2,113,766,645.05Global Median: 1,146,734,693.424
Levered free cash flow is $63.35M, above the global median of $16.24MNotable
Levered free cash flow (USD): 63,346,170.578Global Median: 16,239,329.704
Companies that share the same coordination system — how they create, deliver, or capture value.
Zhejiang Xinan Chemical Co., Ltd.
Tier 1ProductionThroughput-Bound ConversionRuleFlow
Albany International Corp.
Tier 1ProductionThroughput-Bound ConversionFlowRule
China Automotive Engineering Corporation
Tier 1ProductionThroughput-Bound ConversionSenseMakingRule
Shriram Pistons & Rings Ltd.
Tier 1ProductionThroughput-Bound ConversionFlowRule
Sansera Engineering Ltd.
Tier 1ProductionThroughput-Bound ConversionFlowRule
Wuxi Huaguang Environment Co., Ltd.
Tier 1ProductionThroughput-Bound ConversionRuleSenseMaking
Guangzhou Kingmed Diagnostics Group Co. Ltd.
Tier 1ProductionThroughput-Bound ConversionRuleFlow
Sineng Electric Co., Ltd.
Tier 1ProductionThroughput-Bound ConversionRuleFlow
Shanghai Feilo Acoustics Co., Ltd.
Tier 1ProductionThroughput-Bound ConversionRuleSenseMaking
Jiamei Food Packaging Co., Ltd.
Tier 1ProductionThroughput-Bound ConversionFlowRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Pharma Research Products Co., Ltd
10 interpretationsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesCash Backing With Revenue And Income StreaksROE, ROA, And Operating ROA ElevatedOperating Income Growing With Multi-Year Revenue GrowthMulti-Year Revenue, Profit, And Income GrowthIndustry-Benchmarked Return on Capital ElevatedIndustry-Benchmarked ROA and Margin ElevatedThree Margin Ratios Elevated Across Gross, Operating, And Net LevelsMulti-Year Revenue And Profit GrowthThree Asset-Base Ratios Elevated
NVIDIA Corporation
10 interpretationsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesCash Backing With Revenue And Income StreaksROE, ROA, And Operating ROA ElevatedOperating Income Growing With Multi-Year Revenue GrowthMulti-Year Revenue, Profit, And Income GrowthIndustry-Benchmarked Return on Capital ElevatedIndustry-Benchmarked ROA and Margin ElevatedThree Margin Ratios Elevated Across Gross, Operating, And Net LevelsMulti-Year Revenue And Profit GrowthThree Asset-Base Ratios Elevated
Groupe Dynamite Inc.
9 interpretationsCash Backing With Revenue And Income StreaksROE, ROA, And Operating ROA ElevatedOperating Income Growing With Multi-Year Revenue GrowthMulti-Year Revenue, Profit, And Income GrowthUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility ElevatedIndustry-Benchmarked Return on Capital ElevatedThree Margin Ratios Elevated Across Gross, Operating, And Net LevelsMulti-Year Revenue And Profit GrowthThree Asset-Base Ratios Elevated